1. Home
  2. TILE vs SNDX Comparison

TILE vs SNDX Comparison

Compare TILE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interface Inc.

TILE

Interface Inc.

HOLD

Current Price

$31.49

Market Cap

1.7B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.58

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TILE
SNDX
Founded
1973
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
TILE
SNDX
Price
$31.49
$20.58
Analyst Decision
Buy
Strong Buy
Analyst Count
1
13
Target Price
$36.00
$80.23
AVG Volume (30 Days)
303.0K
1.2M
Earning Date
02-24-2026
03-02-2026
Dividend Yield
0.26%
N/A
EPS Growth
33.41
N/A
EPS
1.92
N/A
Revenue
$1,372,471,000.00
$111,304,000.00
Revenue This Year
$7.55
$617.40
Revenue Next Year
$4.73
$115.70
P/E Ratio
$16.26
N/A
Revenue Growth
5.11
595.65
52 Week Low
$17.24
$8.58
52 Week High
$32.15
$22.73

Technical Indicators

Market Signals
Indicator
TILE
SNDX
Relative Strength Index (RSI) 65.35 50.00
Support Level $30.87 $19.79
Resistance Level $32.15 $22.18
Average True Range (ATR) 0.78 1.05
MACD 0.07 -0.08
Stochastic Oscillator 83.52 39.46

Price Performance

Historical Comparison
TILE
SNDX

About TILE Interface Inc.

Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: